Alnylam (ALNY) Q4 2025 earnings review
Historic Pivot: AMVUTTRA Launch Drives First Profitable Year
Alnylam has successfully transitioned from a cash-burning biotech to a profitable commercial leader. Q4 results were explosive: Total Revenue grew 85% YoY to $1.1B, driven by a 121% surge in Net Product Revenues. The catalyst is AMVUTTRA, which generated $827M in the quarter (up 189% YoY) following its U.S. label expansion for cardiomyopathy. Crucially, the company posted positive GAAP Net Income of $112M (vs. an $84M loss last year) and achieved full-year profitability. Guidance for FY26 suggests this momentum will continue, projecting ~70% product revenue growth at the midpoint.
🐂 Bull Case
The ATTR-Cardiomyopathy launch is executing perfectly. TTR franchise revenue hit $858M in Q4 (+151% YoY). With EU/Japan launches ramping in 2026, the $4.4B-$4.7B FY26 guidance for TTR looks achievable.
Revenue grew 85% YoY while GAAP SG&A grew only 10% and R&D grew 24%. The company is finally scaling, allowing revenue dollars to fall to the bottom line.
🐻 Bear Case
Success has a cost. Cost of Goods Sold surged 161% YoY, outpacing revenue growth. Gross margin compressed as AMVUTTRA sales triggered higher blended royalty rates (likely to Sanofi/Regeneron).
The DOJ subpoena regarding price reporting (disclosed in Q3) remains an unresolved risk factor. While operations are strong, government investigations can lead to unpredictable fines or headline risk.
⚖️ Verdict: 🟢🟢
Strong Buy. This is a textbook commercial inflection point. The J-curve in revenue and earnings validates the platform. While royalty costs are rising, the volume growth from AMVUTTRA is overwhelming the headwinds.
Key Themes
AMVUTTRA: The Blockbuster Engine
AMVUTTRA is cannibalizing the legacy ONPATTRO product faster than expected, but the net result is massively positive. Q4 AMVUTTRA sales were $827M vs ONPATTRO's $32M. The label expansion into cardiomyopathy has transformed the company's financial profile. FY26 guidance implies the TTR franchise will nearly double again.
Financial Discipline & Operating Leverage
Accelerating. For the first time, Alnylam is demonstrating true operating leverage. In Q4, Total Revenue increased by $504M YoY, while total Operating Costs increased by only $267M. This discipline allowed the company to post a $132M GAAP Operating Profit compared to a $105M loss in the prior year period.
Royalty Burden Weighing on Gross Margins
Cost of Goods Sold (COGS) is rising significantly faster than revenue. COGS was 26.9% of net product revenues in Q4 2025, up from 22.8% in Q4 2024. Management attributes this to 'increased sales of AMVUTTRA and an associated increase in the blended royalty rate.' As AMVUTTRA scales, Alnylam retains a smaller percentage of each incremental dollar compared to its older portfolio.
Alnylam 2030 Strategy
Management launched a new 5-year plan focusing on 'durable TTR leadership' and 'sustainable innovation.' While standard corporate messaging, the key tangible targets are the pipeline expansions: 4 clinical readouts and 3 Phase 2 initiations scheduled for 2026. This signals a shift from a single-product story to a platform scaling phase.
DOJ Subpoena / Legal Risk
While not detailed in the Q4 release, the Q3 call disclosed a subpoena from the U.S. Attorney's Office regarding government price reporting for key products. The Q4 report lists 'outcome of litigation and government investigations' as a risk factor. In the absence of a clearance, this remains a tail risk for fines or pricing adjustments.
Other KPIs
Up from $2.69B a year ago. The company is now self-funding through operations, removing the risk of dilutive equity raises in the near term.
Stable/Growth. GIVLAARI and OXLUMO grew 26% YoY combined. While overshadowed by TTR, this segment provides a steady $500M+ annual run rate with 18% annual growth.
Reversing. A massive swing from a $278M loss in FY24. This confirms the business model has crossed the breakeven threshold permanently.
Guidance
Accelerating (in absolute terms). Represents 64-77% growth vs FY25. The midpoint ($5.1B) implies the company will add over $2B in new product sales in a single year, driven almost entirely by AMVUTTRA's continued global rollout.
Accelerating. Implies ~83% growth at the midpoint over FY25's $2.49B. This guidance confirms management expects no near-term saturation in the ATTR-CM market.
Decelerating growth. Expenses are guided to grow ~26% at midpoint vs FY25 ($2.18B), which is significantly slower than the projected ~70% revenue growth. This confirms continued margin expansion.
Key Questions
Royalty Rate Ceiling
COGS as a percentage of revenue hit nearly 27% in Q4 due to AMVUTTRA royalties. Is this the ceiling, or will margin compression continue as volumes scale further in FY26?
Ex-US Launch Cadence
How much of the aggressive FY26 TTR guidance ($4.4-4.7B) relies on successful pricing and reimbursement in Europe/Japan versus continued US penetration?
DOJ Subpoena Update
Are there any updates regarding the scope or status of the U.S. Attorney's Office subpoena received in Q3 regarding price reporting? Has the company accrued any reserves for this?